In a Law360 article, health care partner Margaux Hall (Washington, D.C.) examines how biopharmaceutical manufacturers and investors should approach commercialization of emerging therapies in light of legal and regulatory uncertainty as the Biden administration rolls out its agenda for biopharmaceutical innovation and drug pricing.
Margaux analyzes three key drug pricing and market access questions to consider when planning for the launch of a therapy.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.